secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-08-06T20:16:26+00:00
Accession:  0001437749-26-026275
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma Q2 net loss $4.1M; cash $13.0M; PH-762 Phase 1b completed
---------------------------------------------------------------------

- Net loss of $4.1M for Q2 2026 vs $2.2M in Q2 2025, driven by higher R&D spend.
- Cash and equivalents $13.0M at June 30, 2026, down from $21.0M at Dec 31, 2025.
- R&D expenses $3.1M in Q2, up 187% YoY on nonclinical toxicology and CMC costs.
- Phase 1b trial of PH-762 completed; FDA meeting requested in Q3 2026 for next steps.
- Established ATM equity offering up to $6.36M in April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926026275/0001437749-26-026275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926026275/phio20260519_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-026275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer